Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Clinical trials sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., explained in plain language.
-
New COPD treatment enters final safety check
Disease control Not yet recruitingThis study aims to check the safety of an inhaled medicine called TQC3721 for people with moderate to severe COPD, a serious lung disease. It will enroll 800 patients who will use the medicine for 48 weeks while researchers monitor for side effects and track breathing problems. T…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New lung cancer drug trial seeks to control advanced disease
Disease control Not yet recruitingThis clinical trial is testing a new drug called TQB6411 for people with advanced lung cancer. The study aims to find the safest and most effective dose while measuring how well the drug controls cancer growth and shrinks tumors. Researchers will enroll 465 participants to evalua…
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New inhaler aims to help COPD patients breathe easier
Disease control Not yet recruitingThis large, late-stage trial is testing whether a new inhaled medicine called TQC3721 can help people with moderate-to-severe COPD breathe better and have fewer serious flare-ups. About 666 adults aged 40-80 with a significant smoking history will use the inhaler or a placebo for…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New drug trial offers hope for shrinking painful, untreatable tumors
Disease control Not yet recruitingThis study is testing whether an oral capsule called TQ-B3234 can shrink painful, inoperable tumors in adults with neurofibromatosis type 1 (NF1). It will compare the drug to a placebo (a dummy pill) in 177 participants over 24 weeks to see if it reduces tumor size and improves p…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
New pill targets Tough-to-Treat prostate cancer in early trial
Disease control Not yet recruitingThis early-stage study is testing a new oral medication called TQB3201 for men with advanced prostate cancer that has spread and is no longer responding to standard hormone-blocking treatments. The main goals are to find a safe dose, see how the body processes the drug, and get a…
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New pill tested for Tough-to-Treat cancers
Disease control Not yet recruitingThis is the first time a new oral drug called TQB3217 is being tested in people. The main goal is to find a safe dose and see how the body processes it in 40 adults with advanced solid tumors that have stopped responding to standard treatments. Researchers will also get an early …
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
First human test of experimental cancer drug begins
Disease control Not yet recruitingThis is the first human study of an experimental cancer drug called TQB3142. It aims to find the safest dose and understand how the drug moves through the body in 66 adults with advanced cancers that have stopped responding to standard treatments. The main goal is to check for si…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
First human test: can liver patients safely take new blood disorder drug?
Knowledge-focused Not yet recruitingThis early study aims to understand how a single dose of the experimental drug TQ05105 is processed by the body in people with mild or moderate liver problems, compared to healthy people. It will involve 24 adults to measure drug levels in the blood and check for safety. The goal…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC